Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase IIa, Randomized, Double-blind, Placebo-controlled Study to Evaluate Safety, Tolerability, and Pharmacodynamics of AZD4831 (Mitiperstat) in Participants With Non-cirrhotic Non-alcoholic Steatohepatitis (NASH) With Fibrosis

NCT05638737 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT05638737
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05638737 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase IIa, Randomized, Double-blind, Placebo-controlled Study to Evaluate Safety, Tolerability, and Pharmacodynamics of AZD4831 (Mitiperstat) in Participants With Non-cirrhotic Non-alcoholic Steatohepatitis (NASH) With Fibrosis
Lead sponsor
AstraZeneca
Phase
Phase 2
Overall status
Completed
Start date
October 26, 2022
Completion date
April 4, 2024
Enrollment
112 (actual)
Sites
65

Conditions

As the registry lists them; a condition with its own page is linked.

non-cirrhotic non-alcoholic steatohepatitis with fibrosis